

LifeSci Biotechnology Clinical Trials Index

4/13/2021

Effective at the market close on Thursdsay, April 15, 2021, <u>FPRX will be removed from the</u> <u>LifeSci Biotechnology Clinical Trials Index</u> and its values will be redistributed to the remaining index components based on their weights.

• On March 4, 2021, Five Prime Therapeutics agreed to be acquired by Amgen for \$38.00 per share in cash.